Trevarx Biomedical develops small molecule radiopharmaceuticals that target PARP-1 expressing tumors, delivering lethal alpha radiation directly to cancer cell nuclei to induce double-stranded DNA breaks. Their companion diagnostic predicts patient response to PARP inhibitors, enabling tailored treatment while minimizing unnecessary toxicity.
Funding
$650K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers express PARP-1, a protein involved in DNA repair, and current PARP inhibitors have shown promise in treating these cancers. However, predicting which patients will respond to PARP inhibitors remains a challenge, and these treatments can cause unnecessary toxicity in non-responsive individuals. Furthermore, delivering targeted radiation directly to cancer cell nuclei can be difficult with existing radiotherapeutic approaches.
Solution
Trevarx Biomedical is developing small molecule radiopharmaceuticals that selectively target PARP-1 expressing tumors. These radiopharmaceuticals deliver alpha radiation directly to the cancer cell nuclei, inducing double-stranded DNA breaks and cell death. Trevarx is also developing a companion diagnostic to identify patients most likely to respond to PARP inhibitors and their radiotherapeutic, enabling personalized treatment strategies. This diagnostic aims to predict patient response, guide effective treatment, and minimize unnecessary toxicity.
Target Audience
The primary target audience includes oncologists specializing in breast, ovarian, and prostate cancer, as well as patients with PARP-1 expressing tumors who may benefit from targeted alpha therapy.
Features
- Small molecule radiopharmaceutical platform for targeted delivery of alpha radiation to PARP-1 expressing tumors.
- Utilizes Astatine-211, an alpha-emitting radioisotope, to deliver a lethal radioactive charge directly to the cancer cell nucleus.
- Companion diagnostic to identify PARP-1 expressing tumors and predict patient response to PARP inhibitors and Trevarx's radiotherapeutic.
- Induces double-stranded DNA breaks in cancer cells, leading to cell death.
- Designed for rapid clearance from the body to minimize off-target radiation exposure.